Chapter 14 - Challenges to molecularly imprinted polymers in competition with biosensors at commercial scale

Abstract

Rapid diagnosis of infectious diseases and its timely treatment are critical determinants that can reduce the disease outbreaks, a lesson much learnt from the COVID-19 pandemic. Advances in biosensor technologies have eased the point-of-care diagnostics and surpassed the conventional standards in regard to accuracy, time, and cost. Modern biosensors based on micro- and nanofabrication technologies with diverse sensing strategies were introduced with great excitement for having potential of producing devices having lab-on-a-chip, but unexpectedly only few of them have been able to make a place in the market.